George Schmieder, DO
Dermatology · Orange Park, FLNPI 1578537759
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,023 of the $12,138 with a category attached, or 82.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,457 and has fallen 51.9% since, to $1,181 in 2025.
Across 503 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB Biosciences Inc.$1K
- Sanofi$1K
- Pfizer$1K
- Regeneron Healthcare Solutions, Inc.$832
- Lilly USA, LLC$781
- plus $4K from 28 others
Across 460 payments — averaging $5852.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Eli Lilly$557K
- UCB SA$371K
- AbbVie$326K
- Janssen Research & Development, LLC$186K
- LEO Pharma AS$69K
- plus $27K from 3 others
What the payments were for
- Speaking & faculty fees$520%
- Travel & lodging$1,17110%
- Food & beverage$10,02383%
- Education$8927%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 110 | $2,207 |
| UCB Biosciences Inc. | 12 | $1,451 |
| Sanofi | 43 | $1,337 |
| Pfizer | 58 | $1,224 |
| Regeneron Healthcare Solutions, Inc. | 26 | $832 |
| Lilly USA, LLC | 44 | $781 |
| LEO Pharma Inc. | 38 | $739 |
| Johnson & Johnson | 47 | $665 |
| Sun Pharmaceutical Industries Inc. | 14 | $387 |
| Amgen | 14 | $341 |
| Galderma Laboratories, L.p. | 6 | $277 |
| Novartis | 16 | $261 |
| Janssen Scientific Affairs, LLC | 2 | $185 |
| Bristol Myers Squibb | 5 | $172 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 10 | $157 |
| Sebela Pharmaceuticals Inc. | 7 | $124 |
| Kerecis Limited | 2 | $120 |
| E.r. Squibb & Sons, L.L.C. | 5 | $118 |
| UCB, Inc. | 6 | $109 |
| Incyte Corporation | 5 | $103 |
| Genentech USA, Inc. | 6 | $81 |
| Dermavant Sciences, Inc. | 3 | $75 |
| Organogenesis Inc. | 4 | $73 |
| Melinta Therapeutics, LLC | 4 | $64 |
| Boehringer Ingelheim | 3 | $61 |
| VYNE Pharmaceuticals Inc. | 2 | $32 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $29 |
| Sandoz | 2 | $28 |
| Mylan Pharmaceuticals Inc. | 2 | $25 |
| Arcutis Biotherapeutics, Inc. | 1 | $21 |
| Almirall LLC | 1 | $17 |
| EPI Health, LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Dermira, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimekizumab$586
- EUCRISA$559
- Kerecis Omega3 Marigen$401
- DUPIXENT$351
- Rinvoq$125
- EPIDUO FORTE$121
- LIBTAYO$104
- Humira$102
- Kerecis Omega3 SurgiClose$100
- ILUMYA$100
- Tremfya$100
How this compares
$12,138 in reported general payments places this provider in the 80th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 22 | $78,582 |
| Gentamicin Sulfate | 247 | $8,067 |
| Doxycycline Hyclate | 754 | $5,944 |
| Fluorouracil | 37 | $2,977 |
| Cephalexin | 36 | $233 |
| Triamcinolone Acetonide | 19 | $179 |
| Ketoconazole | 12 | $168 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Orange Park
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.